Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon‐α and ribavirin in chronic hepatitis C virus patients
Pascal Frei(University Hospital Zurich), Monika Rau(LMU Klinikum), Reto Kofmehl(University of Zurich), Markus H. Heim(University of Basel), Francesco Negro(University Hospital of Geneva), Ulrike Held(University of British Columbia), Beat Müllhaupt(University Hospital of Zurich), Andreas Geier(Swiss Integrative Center for Human Health), Darius Moradpour(University Hospital of Lausanne), Anna‐Kathrin Leucht(University Hospital Zurich), Andreas Cerny(Epatocentro Ticino), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Jean‐François Dufour(Universidad Iberoamericana), Tilman Gerlach(Kantonsspital St. Gallen), Christine N. Manser(University Hospital Zurich), Katharina Baur(University Hospital Zurich), Johannes Schmitt(University Hospital Zurich)
Cited by 14
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k